Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.St Jude awarded US patent for depression therapy
Brodmann Area 25 is a structure within the subcollosal gyrus region of the brain. It is the focus of the St Jude Medical Broaden study, which is evaluating
Brodmann Area 25 is a structure within the subcollosal gyrus region of the brain. It is the focus of the St Jude Medical Broaden study, which is evaluating
The HumanHT-12 BeadChip includes over 48,000 probes per sample and is priced at $75, supporting a total cost of $100 per sample including labeling reagents. Illumina expects to
In accordance with Indian regulations, Fresenius Kabi also announced a public offer to acquire up to a further 20% shareholding for a price of INR76.50 per share in
Under the terms of this license agreement, Nippon Shinyaku will receive from Actelion an upfront payment and additional milestone payments based on development stage and sales achievement. Nippon
With these openings, InfuScience has expanded the company’s pharmacy network to eight locations throughout the US. The Jacksonville and Tampa facilities include a state-of-the-art compounding pharmacy, an ambulatory
The company believes that it is the first to file an ANDA with a Paragraph IV certification against Monistat 1. Perrigo also notified Johnson & Johnson, the new
Felodipine extended-release tablets are the generic version of AstraZeneca Pharmaceutical’s Plendil extended-release tablets. The company will begin shipping the product immediately.
Under these agreements, Digilab Genomic Solutions (DGS) and CyBio will collaborate on manufacture and distribution of the DGS Hummingbird-Plus instrument. Digilab will supply Hummingbird dispensing heads and cassettes
The primary endpoint of the Treating to New Targets (TNT) study was the reduction of major cardiovascular events, including death from heart disease, non-fatal heart attacks, resuscitated cardiac
Sigma-Tau is developing this product as an emergency treatment for severe and complicated malaria in collaboration with the Walter Reed Army Institute of Research. Gregg Lapointe, Sigma-Tau Pharmaceutical’s